Drugs / BAT1806
Trials 4 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 13 trials | ||||||
| Phase 1 | NCT06262477 | Jan → Sep 2024 | — | Biogen | Completed | No outcome recorded |
| Phase 1 | NCT05968508 | Aug 2023 → Oct 2024 | — | Bio-Thera Solutions | Completed | No outcome recorded |
| Phase 1 | NCT03606876 | Jun 2018 → Jul 2019 | rheumatoid arthritis | Bio-Thera Solutions | Completed | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT03830203 | Dec 2018 → Jan 2021 | rheumatoid arthritis | Bio-Thera Solutions | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BAT1806 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03606876 ↗ |
| Known as | BAT1806 SC | “This study compared the pharmacokinetics (PK), safety, and immunogenicity of the Tocilizumab biosimilar, BAT1806 SC (Tocilizumab biosimilar, Subcutaneous Injection), with...” PMID 41069221 ↗ Oct 2025 |
| Known as | BIIB800 | “A phase 3, randomized, double-blind, active-controlled clinical trial to compare BAT1806/BIIB800, a tocilizumab biosimilar, with tocilizumab reference product in participants...” PMID 39244595 ↗ Sep 2024 |
| Route | Intravenous | “single intravenous drip” NCT03606876 ↗ |